Data Article

Data on distant metastasis and survival after locoregional recurrence following nipple-sparing mastectomy and immediate breast reconstruction

Zhen-Yu Wu\textsuperscript{a,b}, Hyun Ho Han\textsuperscript{c}, Hee Jeong Kim\textsuperscript{a}, Jongwon Lee\textsuperscript{a}, Il Yong Chung\textsuperscript{a}, Jisun Kim\textsuperscript{a}, Saebyeol Lee\textsuperscript{a}, Jin Sup Eom\textsuperscript{c}, Sung-Bae Kim\textsuperscript{d}, Gyungyub Gong\textsuperscript{e}, Hak Hee Kim\textsuperscript{f}, Byung-Ho Son\textsuperscript{a}, Sei-Hyun Ahn\textsuperscript{a}, BeomSeok Ko\textsuperscript{a,*}

\textsuperscript{a}Division of Breast Surgery, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul 05505, Republic of Korea
\textsuperscript{b}Department of Breast Surgery, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China
\textsuperscript{c}Department of Plastic Surgery, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul 05505, Republic of Korea
\textsuperscript{d}Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul 05505, Republic of Korea
\textsuperscript{e}Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul 05505, Republic of Korea
\textsuperscript{f}Department of Radiology, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul 05505, Republic of Korea

\textbf{A B S T R A C T}

Nipple-spring mastectomy (NSM) with immediate breast reconstruction is being increasingly used in the treatment of breast cancer \cite{1}. However, there are limited available data on the prognostic implications of locoregional recurrence (LRR) following this surgical procedure. This article is a supplementary resource of the original research article by Wu ZY et al. entitled “Locoregional Recurrence Following Nipple-Sparing Mastectomy with Immediate Breast Reconstruction: Patterns and Prognostic Significance” \cite{2} and presents data

\textbf{A R T I C L E   I N F O}

Article history:
Received 13 January 2021
Revised 31 January 2021
Accepted 2 February 2021
Available online 5 February 2021

DOI of original article: 10.1016/j.ejso.2021.01.006
* Corresponding author.
\textit{E-mail address:} spdokterko@gmail.com (B. Ko).
Social media: \(\text{Twitter}\) (B. Ko)

https://doi.org/10.1016/j.dib.2021.106837
2352-3409/© 2021 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
Keywords:
- Breast cancer
- Nipple-sparing mastectomy
- Immediate breast reconstruction
- Locoregional recurrence
- Distant metastasis
- Prognosis

regarding the subsequent distant metastasis following the first LRR, as well as the prognoses for isolated local recurrences according to the site of recurrence after NSM and immediate breast reconstruction for primary breast cancer. Data from a total of 1,696 patients with primary breast cancer who underwent NSM with immediate reconstruction from March 2003 to December 2016 at the Asan Medical Center, Seoul, Korea, were retrospectively reviewed. An LRR as the first event was found to have developed in 172 patients. Among these, 117 cases (6.9%) involved isolated local recurrence, including 52 cases (3.1%) of nipple-areola complex recurrence, 41 cases (2.4%) of skin/subcutaneous recurrence, and 24 cases (1.4%) of chest wall recurrence. Kaplan-Meier survival analysis and the log-rank test were performed to compare the subgroups of local recurrence. In 172 patients with LRR, subsequent distant metastases were observed in 30 cases (17.4%). Our data may be helpful for conducting further in-depth investigations on salvage treatment options in patients with LRR following NSM and immediate breast reconstruction. © 2021 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)

Specifications Table

| Subject | Surgery, Oncology |
|---------|-------------------|
| Specific subject area | Prognosis associated with the recurrence after breast cancer treatment |
| Type of data | Table |
| How data were acquired | Retrospective clinical chart review |
| Data format | Raw |
| Parameters for data collection | Patients with locoregional recurrence as the first event after nipple-sparing mastectomy and immediate breast reconstruction for primary breast cancer were included in this study. |
| Description of data collection | Patient data and medical records were obtained from a prospectively maintained database and were documented in an Excel dataset. |
| Data source location | Institution: Asan Medical Center |
| City/Town/Region: Seoul |
| Country: South Korea |
| Data accessibility | With the article. Raw data are uploaded to Mendeley Data. Direct URL to raw data: http://dx.doi.org/10.17632/5kJj57f5dm.1 |
| Related research article | Wu ZY, Han HH, Kim HJ, Lee J, Chung JY, Kim J, Lee S, Han J, Eom JS, Kim SB, Gong G, Kim HH, Son BH, Ahn SH, Ko B. Locoregional recurrence following nipple-sparing mastectomy with immediate breast reconstruction: Patterns and prognostic significance, Eur. J. Surg. Oncol. 2021 Jan 13:S0748–7983(21)00,006–8, http://dx.doi.org/10.1016/j.ejso.2021.01.006. Online ahead of print. |

Value of the Data

- Considering the very limited available data on locoregional recurrence (LRR) outcomes following nipple-sparing mastectomy (NSM) and immediate breast reconstruction, our current data provide important initial insights that will assist with the appropriate management and surveillance of this patient population.
Our data may be useful to those estimating prognosis following an LRR in patients who underwent NSM and immediate breast reconstruction.

Our data would allow researchers to conduct further in-depth studies on salvage treatment options in patients with LRR following NSM and immediate breast reconstruction.

1. Data Description

We present supporting data related to the research article “Locoregional Recurrence Following Nipple-Sparing Mastectomy with Immediate Breast Reconstruction: Patterns and Prognostic Significance” by Wu et al. Table 1 contains the characteristics of the 30 patients who subsequently developed distant metastasis after the first LRR following NSM and immediate breast reconstruction. For each case, the age at diagnosis of the primary tumor, the site of distant metastasis, the corresponding site of first LRR, the primary tumor and LRR molecular subtypes, the time to first LRR, the time interval between LRR and distant metastasis, and the survival status at the last follow-up are shown.

Fig. 1 shows the Kaplan–Meier curves for disease-free survival (A) and distant metastasis-free survival (B) in accordance with the site of local recurrence after NSM and immediate breast reconstruction. Among the patient cohort, there were 52 cases of nipple-areola complex recurrence, 41 cases of skin/subcutaneous recurrence, and 24 cases of chest wall recurrence. The relevant raw data are provided in the supplementary file.

2. Experimental Design, Materials and Methods

This retrospective study included all patients with primary breast cancer who underwent NSM and immediate breast reconstruction at the Asan Medical Center, Seoul, Korea, between March 2003 and December 2016. LRR as the first event was found to have developed in 172 of the 1696 breast cancer patients in our cohort. Cases of LRR diagnosed with a simultaneous distant metastasis were excluded from this subgroup.

Recurrences and metastases were assessed by clinical examination and chest radiography during every follow-up visit. Abnormal clinical findings were evaluated through further studies, including ultrasonography, computed tomography of the chest, and bone scanning. Fine needle aspiration, core needle or excisional biopsies were performed to evaluate suspected locoregional lesions. Patients who failed to be present for scheduled examinations were contacted via telephone to confirm that they were alive. LRRs were classified as biopsy-proven local recurrences in the ipsilateral nipple-areola complex, skin/subcutaneous layer, or chest wall, and as regional recurrences during instances of carcinoma metastases involving the ipsilateral axillary, supraclavicular, or internal mammary lymph node. Any other site of recurrence was considered to be distant metastasis. Lesions with a clear evidence of distant metastasis during imaging evaluation were considered as recurrence without pathological examination.

Endpoints of interest included disease-free survival (DFS) and distant metastasis-free survival (DMFS) after LRR as the first event. Post-recurrence DFS was defined as the interval from the date of LRR salvage treatment to any second recurrence. Post-recurrence DMFS was defined as the interval from the date of LRR salvage treatment to the subsequent occurrence of a distant metastasis. Survival rates were estimated using the Kaplan-Meier method and compared using the log-rank test. All statistical analyses were performed using SPSS, version 24.0 for Windows (IBM Corp., Armonk, NY, USA).

Ethics Statement

The study protocol was approved by the Institutional Review Board of the Asan Medical Center (Approval No. 20,200,712), and all experiments were conducted in accordance with the
| No. | Age at diagnosis of years | Site of DM | Site of LRR as 1st event | Molecular subtype (PT) | Molecular subtype (LRR) | Time to LRR, months | Time interval between LRR and DM, months | Survival status |
|-----|--------------------------|------------|--------------------------|------------------------|------------------------|---------------------|------------------------------------------|----------------|
| 1   | 36                       | Brain, Lung| SCR                      | HR+/HER2-              | TN                     | 3                   | 19                                       | Alive          |
| 2   | 27                       | Lung, Distant LN| CWR                    | HR+/HER2-              | HR+/HER2-              | 5                   | 9                                        | Alive          |
| 3   | 37                       | Distant LN | ALN                      | HR-/HER2+              | HR-/HER2+              | 6                   | 9                                        | Dead           |
| 4   | 35                       | Lung       | CWR                      | HR+/HER2-              | HR+/HER2-              | 7                   | 72                                       | Dead           |
| 5   | 32                       | Bone, Pleura, Liver | SCR                  | HR+/HER2+              | HR-/HER2+              | 7                   | 7                                        | Alive          |
| 6   | 46                       | Distant lymph nodes | ALN, SCLN            | HR+/HER2-              | TN                     | 8                   | 10                                       | Alive          |
| 7   | 26                       | Liver      | ALN                      | HR+/HER2-              | HR+/HER2-              | 9                   | 28                                       | Dead           |
| 8   | 39                       | Lung       | ALN                      | TN                     | HR-/HER2+              | 9                   | 1                                        | Dead           |
| 9   | 32                       | Liver, Lung, Bone, Distant LN | NCR                  | HR-/HER2+              | HR-/HER2+              | 12                  | 16                                       | Dead           |
| 10  | 51                       | Distant LN, Lung, Bone | ALN                  | HR-/HER2+              | HR-/HER2+              | 13                  | 10                                       | Dead           |
| 11  | 31                       | Distant LN | NCR                      | HR-/HER2+              | HR-/HER2+              | 14                  | 5                                        | Alive          |
| 12  | 31                       | Lung       | SCR                      | HR+/HER2-              | HR-/HER2+              | 18                  | 24                                       | Alive          |
| 13  | 26                       | Lung, Bone | SCLN                    | HR+/HER2+              | HR+/HER2+              | 18                  | 11                                       | Dead           |
| 14  | 34                       | Bone, Distant LN | IMLN                  | HR-/HER2+              | HR-/HER2+              | 19                  | 33                                       | Alive          |
| 15  | 35                       | Distant LN | ALN                      | TN                     | TN                     | 19                  | 45                                       | Dead           |
| 16  | 28                       | Lung, Pleura, Bone, Distant LN | SCR                    | HR-/HER2+              | HR-/HER2-              | 20                  | 59                                       | Alive          |
| 17  | 44                       | Lung       | ALN, SCLN                | HR-/HER2+              | HR-/HER2+              | 29                  | 5                                        | Dead           |
| 18  | 33                       | Bone       | ALN                      | HR-/HER2+              | HR-/HER2+              | 31                  | 14                                       | Alive          |
| 19  | 42                       | Liver, Lung | ALN                    | HR-/HER2+              | HR-/HER2-              | 34                  | 41                                       | Dead           |
| 20  | 45                       | Liver, Bone, Distant LN | ALN                  | HR-/HER2+              | HR-/HER2-              | 36                  | 39                                       | Dead           |
| 21  | 32                       | Liver      | CWR                      | HR+/HER2+              | HR-/HER2+              | 46                  | 20                                       | Alive          |
| 22  | 43                       | Liver, Pleura | IMLN                  | HR+/HER2+              | HR-/HER2+              | 58                  | 26                                       | Dead           |
| 23  | 29                       | Lung       | SCR                      | HR+/HER2+              | HR-/HER2-              | 61                  | 87                                       | Alive          |
| 24  | 24                       | Bone       | IMLN                     | HR+/HER2+              | HR-/HER2+              | 76                  | 21                                       | Alive          |
| 25  | 40                       | Liver, Bone, Distant LN | CWR                | HR+/HER2-              | HR-/HER2+              | 84                  | 24                                       | Dead           |
| 26  | 48                       | Bone, Liver | ALN                   | HR+/HER2+              | HR-/HER2+              | 88                  | 53                                       | Alive          |
| 27  | 38                       | Bone       | ALN                      | HR-/HER2+              | HR-/HER2-              | 90                  | 26                                       | Dead           |
| 28  | 50                       | Distant LN | SCR                      | HR-/HER2+              | HR-/HER2+              | 103                 | 22                                       | Alive          |
| 29  | 44                       | Brain, Bone, Pleura | SCLN, IMLN          | HR+/HER2-              | HR-/HER2-              | 119                 | 25                                       | Alive          |
| 30  | 44                       | Lung       | ALN                      | HR+/HER2+              | TN                     | 144                 | 17                                       | Alive          |

ALN, axillary lymph node; CWR, chest wall recurrence; DM, distant metastasis; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; IMLN, internal mammary lymph node; LN, lymph node; LRR, locoregional recurrence; NCR, nipple-areola complex recurrence; NSM, nipple-sparing mastectomy; PT, primary tumor; SCLN, supraclavicular lymph node; SCR, skin or subcutaneous recurrence; TN, triple negative.
Fig. 1. Kaplan–Meier survival analysis of the disease-free survival (A) and distant metastasis-free survival (B), in accordance with the site of local recurrence after nipple-sparing mastectomy and immediate breast reconstruction. CWR, chest wall recurrence; NCR, nipple-areola complex recurrence; SCR, skin or subcutaneous recurrence.

Declaration of Helsinki. The requirement for informed consent was waived since our study was a retrospective review of patient records.

CRediT Author Statement

Zhen-Yu Wu: Conceptualization, Methodology, Formal analysis, Investigation, Data curation, Writing original draft, Supervision; Hyun Ho Han: Methodology, Investigation, Data curation;
Hee Jeong Kim: Data curtion; Jongwon Lee: Data curtion; Il Yong Chung: Data curtion; Jisun Kim: Data curtion; Saebyeol Lee: Data curtion; Jin Sup Eom: Data curtion; Sung-Bae Kim: Data curtion; Gyungyub Gong: Data curtion; Hak Hee Kim: Data curtion; Byung-Ho Son: Data curtion; Sei-Hyun Ahn: Conceptualization, Methodology; BeomSeok Ko: Conceptualization, Methodology, Validation, Formal analysis, Investigation, Data curtion, Writing review & editing, Supervision, Project administration.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships which have or could be perceived to have influenced the work reported in this article.

Acknowledgments

None.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

References

[1] S.M. Wong, Y.S. Chun, Y. Sagara, M. Golshan, J. Erdmann-Sager, National patterns of breast reconstruction and nipple-sparing mastectomy for breast cancer, 2005-2015, Ann. Surg. Oncol. 26 (2019) 3194–3203.
[2] Z.Y. Wu, H.H. Han, H.J. Kim, J. Lee, I.Y. Chung, J. Kim, et al., Locoregional recurrence following nipple-sparing mastectomy with immediate breast reconstruction: patterns and prognostic significance, Eur. J. Surg. Oncol. (2021 Jan 13) S0748-7983(21)00006-8Online ahead of print, doi:10.1016/j.ejso.2021.01.006.